For the patients with recurrence or metastasis, cisplatin, and paclitaxel drugs‐based chemotherapy together with tumor vascular‐targeting drugs such as bevacizumab (targeting vascular endothelial growth factor, VEGF) have been approved by the food and drug administration (FDA) as the first‐line treatment according to the results of GOG 240 trial (Bradley, & Krishnansu, 2014). The gene discussed is VEGFA; the disease is neoplasm.